Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | BIPARK-I and II: opicapone and levodopa in PD with motor fluctuations

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses a post-hoc analysis of the BIPARK-I and BIPARK-II trials. The results confirm that using a catechol-O-methyltransferase (COMT) inhibitor, such as opicapone, can significantly extend the benefits of levodopa in Parkinson’s disease (PD) patients with motor fluctuations. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).